GB680788A - Pharmaceutical products - Google Patents

Pharmaceutical products

Info

Publication number
GB680788A
GB680788A GB10792/51A GB1079251A GB680788A GB 680788 A GB680788 A GB 680788A GB 10792/51 A GB10792/51 A GB 10792/51A GB 1079251 A GB1079251 A GB 1079251A GB 680788 A GB680788 A GB 680788A
Authority
GB
United Kingdom
Prior art keywords
vaccines
polysaccharide
pharmaceutical product
pyrogenic
pharmaceutical products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB10792/51A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GAF Chemicals Corp
Original Assignee
General Aniline and Film Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Aniline and Film Corp filed Critical General Aniline and Film Corp
Publication of GB680788A publication Critical patent/GB680788A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

680,788. Medicines. GENERAL ANILINE & FILM CORPORATION. May 8, 1951 [May 19, 1950], No. 10792/51. Class 81 (i). A medicine comprises a mixture of a normally pyrogenic pharmaceutical product selected from the group consisting of vaccines, polysaccharide and emulsified fats, and a pre-determined amount of a polyvinyl pyrolidone sufficient to minimize substantially the normal pyrogenic effect of the pharmaceutical product. The vaccines specified are those of typhoid, diphtheria, smallpox, whooping cough and common cold. The polysaccharide sold under the name glucouronic acid is mentioned. U.S.A. Specification 2,265,450 is referred to.
GB10792/51A 1950-05-19 1951-05-08 Pharmaceutical products Expired GB680788A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US680788XA 1950-05-19 1950-05-19

Publications (1)

Publication Number Publication Date
GB680788A true GB680788A (en) 1952-10-08

Family

ID=22080291

Family Applications (1)

Application Number Title Priority Date Filing Date
GB10792/51A Expired GB680788A (en) 1950-05-19 1951-05-08 Pharmaceutical products

Country Status (1)

Country Link
GB (1) GB680788A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707959A (en) * 1952-06-20 1955-05-10 Gen Aniline & Film Corp Tobacco composition and method of minimizing the irritating properties of tobacco
US2904469A (en) * 1957-07-29 1959-09-15 Johnson & Johnson Stabilized aqueous suspension of salicylamide
US2915438A (en) * 1956-08-31 1959-12-01 Ortho Pharma Corp Preparation of brucella antigen
US3041239A (en) * 1959-05-28 1962-06-26 Johnson & Johnson Stable aqueous salicylamide composition and method of preparing same
DE1270223B (en) * 1964-03-20 1968-06-12 Wellcome Found Method for inactivating myxoviruses
US4239664A (en) * 1978-10-31 1980-12-16 Research Corporation Anti-thrombogenic PVP-heparin polymer

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707959A (en) * 1952-06-20 1955-05-10 Gen Aniline & Film Corp Tobacco composition and method of minimizing the irritating properties of tobacco
US2915438A (en) * 1956-08-31 1959-12-01 Ortho Pharma Corp Preparation of brucella antigen
US2904469A (en) * 1957-07-29 1959-09-15 Johnson & Johnson Stabilized aqueous suspension of salicylamide
US3041239A (en) * 1959-05-28 1962-06-26 Johnson & Johnson Stable aqueous salicylamide composition and method of preparing same
DE1270223B (en) * 1964-03-20 1968-06-12 Wellcome Found Method for inactivating myxoviruses
US4239664A (en) * 1978-10-31 1980-12-16 Research Corporation Anti-thrombogenic PVP-heparin polymer

Similar Documents

Publication Publication Date Title
GB1298084A (en) Capsules and other self-supporting medicinal packaging means
GB1380171A (en) Medicinal tablets
GB1510100A (en) Vaccines
GB680788A (en) Pharmaceutical products
IE37602L (en) Cyclocpentane derivatives
GB1256456A (en) Ethylethyleneimine as inactivating agent in antigen-containing pharmaceutical preparations
NO306762B1 (en) Use of lanolin derivatives in conjunction with polyethylene glycol ethers, their mixture and transdermal therapeutic system
Jehn et al. The effect of antimacrophage serum on macrophage-lymphocyte interaction in vitro
Personnel of Naval Laboratory Research Unit No. 1 Attempts to protect against influenza virus with various sulfonamides, acridines and antibiotics
GB1126153A (en) Novel polygalacturonic acid derivative
Magill et al. Antigenically different strains of virus from a localized influenza outbreak
GB1302266A (en)
FR2457282A1 (en) NEW DERIVATIVE OF 1A, 25 DIHYDROXY CHOLECALCIFEROL, ITS PREPARATION METHOD AND ITS APPLICATION AS A MEDICAMENT
GB1212886A (en) Equine vaccine and vaccination treatment
GB533625A (en) Process for the manufacture of tablets from oily active materials
BE788152A (en) THIADIAZOLES USED FOR DISINFECTION OF SEEDS AND AS AN ANTISEPTIC MEDICINAL PRODUCT
GB1300486A (en) Compositions for the treatment of respiratory ailments in man
SU100456A1 (en) Leptospirazna vaccine
FR907481A (en) Process for the preparation of polycondensation products from lactams and amino carbonic acids
GB1254125A (en) Pharmaceutical composition suitable for the treatment of certain vascular diseases
GB1174362A (en) Oral Medicants for Haemorrhoids.
GB1191180A (en) Therapeutic Composition
FR1015147A (en) Process for the preparation of dextran-based products intended for pharmaceutical and therapeutic preparations
IE42043L (en) Influenza type b virus vaccines.
Katoh Studies tetanus and diphtheria vaccination. Part 2. Effectiveness of acetylsalicylic acid administered to alleviate side reaction following inoculation of DPT triple vaccine and its influence on immune response (author's transl)